REVVITY, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Revvity launched the GSP T1D 3plex kit, a CE-IVDR-certified test for early type 1 diabetes detection in children. The kit uses dried blood samples and is available in Europe. The company aims to expand into child health screening and will present related services at an upcoming diabetes conference. Revvity also recently received FDA clearance for a testosterone test.
Revvity (RVTY) reported Q2FY26 results with 3% organic growth and adjusted EPS of $1.41, exceeding guidance. Diagnostics revenue rose 11% organically, while Life Sciences declined 3%. Management raised full-year guidance, citing improved market conditions and strategic reinvestments. Total revenue is projected between $2.83B and $2.86B.
Several biotech stocks hit 52-week highs on September 24, 2026. CareDx (CDNA) rose 13% to $63.09, Grail (GRAL) climbed 15% to $126.81, Adaptive Biotechnologies (ADPT) gained 6% to $29.58, Revvity (RVTY) increased 6% to $152.26, and Twist Bioscience (TWST) surged 16% to $185.22. Key catalysts included regulatory milestones, clinical trial results, and strategic acquisitions.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning RVTY (REVVITY, INC.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 1 bearish.
Recent RVTY coverage spans market movers, financial news and mergers & acquisitions.
In the last 30 days, RVTY insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($1.3M). The most active reporter was Krakowiak Maxwell, Please See Remarks, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Revvity launched the GSP T1D 3plex kit, a CE-IVDR-certified test for early type 1 diabetes detection in children. The kit uses dried blood samples and is available in Europe. The company aims to expand into child health screening and will present related services at an upcoming diabetes conference. Revvity also recently received FDA clearance for a testosterone test.
Earnings beat and guidance raise may support short‑term price upside, but the move is likely muted as the data was released over a month ago.
Higher guidance and product launch support further price gains.
Analyst upgrade may lift Revvity's stock price in the short term.
The insider sale suggests potential downside pressure on Revvity stock.
AlphAI scores every news story that mentions RVTY with an AI model for sentiment and relevance, and aggregates insider trades from REVVITY, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Revvity launched the GSP T1D 3plex kit, a CE-IVDR-certified test for early type 1 diabetes detection in children. The kit uses dried blood samples and is available in Europe. The company aims to expand into child health screening and will present related services at an upcoming diabetes conference. Revvity also recently received FDA clearance for a testosterone test.
2 min readRevvity (RVTY) reported Q2FY26 results with 3% organic growth and adjusted EPS of $1.41, exceeding guidance. Diagnostics revenue rose 11% organically, while Life Sciences declined 3%. Management raised full-year guidance, citing improved market conditions and strategic reinvestments. Total revenue is projected between $2.83B and $2.86B.
2 min readSeveral biotech stocks hit 52-week highs on September 24, 2026. CareDx (CDNA) rose 13% to $63.09, Grail (GRAL) climbed 15% to $126.81, Adaptive Biotechnologies (ADPT) gained 6% to $29.58, Revvity (RVTY) increased 6% to $152.26, and Twist Bioscience (TWST) surged 16% to $185.22. Key catalysts included regulatory milestones, clinical trial results, and strategic acquisitions.
2 min readLeerink Partners raised its price target for Revvity to $160 from $145 and maintained an Outperform rating. The company's stock is currently trading at $142.11, with a 5-day change of -0.84% and a year-to-date change of +46.88%.
1 min readRevvity, Inc. (NYSE:RVTY) SVP Tajinder Vohra sold shares worth $1.0M at $141, reducing his holding by 38%. No insider buying occurred in the past year. Insiders own 0.4% of shares, valued at $67M. The company has 2 identified warning signs.
1 min readVohra Tajinder S (Please See Remarks) sold 7,330 shares of REVVITY, INC. (RVTY) at $140.88 ($1.03M total) on 2026-09-16 under a Rule 10b5-1 trading plan.
1 min readRevvity (NYSE: RVTY) officer Tajinder S. Vohra filed a Rule 144 notice to sell up to 7,330 shares, valued at approximately $1.03 million. The shares stem from restricted stock vesting awards. As of September 16, 2026, Revvity had 111,586,401 common shares outstanding.
1 min readSkyworks Solutions (SWKS) and Qorvo (QRVO) rose 10% and 7% respectively, recovering from prior sell-offs. Axon (AXON) fell 9% after a $1B convertible note sale. Revvity (RVTY) jumped 7% to a 52-week high, citing strong backlog. Dave & Buster's (PLAY) dropped 17% after missing Q2 revenue and EBITDA estimates. Enova (ENVA) tumbled 25% after withdrawing a regulatory application. Sysco (SYY) slid 3% on a 12.3M share offering. Alignment Healthcare (ALHC) fell 18% due to business headwinds. Waystar (W
2 min readRevvity has agreed to acquire Human Cell Design (HCD), a French biotech firm specializing in human cell models for metabolic diseases. The deal, expected to close in Q4 2026, will add HCD's pancreatic beta cell models to Revvity's portfolio, enhancing drug discovery and preclinical research capabilities. HCD's technology complements Revvity's detection and analysis tools, supporting applications in diabetes research and regenerative medicine.
2 min readRevvity, Inc. (NYSE:RVTY) agreed to acquire Human Cell Design SAS, adding its pancreatic beta cell models to support drug discovery. The deal is expected to close in Q4 2026, pending approvals. Revvity specializes in measurement devices and analytical instruments for healthcare and research.
2 min read
